Assessment of Radiolabelled Derivatives of R954 for Detection of Bradykinin B1 Receptor in Cancer Cells: Studies on Glioblastoma Xenografts in Mice.

R954 bradykinin B1 receptor glioblastoma molecular imaging nuclear imaging

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
07 Jul 2024
Historique:
received: 20 06 2024
accepted: 04 07 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 27 7 2024
Statut: epublish

Résumé

Bradykinin B1 receptor (B1R) has garnered attention as a cancer therapeutic and diagnostic target. Several reports on radiolabelled derivatives of B1R antagonists have shown favourable properties as imaging agents in cells highly expressing hB1R following transfection. In the present study, we assessed whether radiolabelled probes can detect B1R endogenously expressed in cancer cells. To this end, we evaluated

Identifiants

pubmed: 39065752
pii: ph17070902
doi: 10.3390/ph17070902
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Miho Shukuri (M)

Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Satoru Onoe (S)

Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Tsubasa Karube (T)

Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Risa Mokudai (R)

Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Hayate Wakui (H)

Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Haruka Asano (H)

Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Shin Murai (S)

Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Hiromichi Akizawa (H)

Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Classifications MeSH